Sign in

    Dina Ramadane

    Biotech Equity Research Associate at Bank of America

    Dina Ramadane is a Biotech Equity Research Associate at Bank of America, specializing in coverage of gene therapy and biotechnology companies such as Bluebird Bio. She is noted for her proactive analysis of industry trends and challenges, particularly in the uptake of new therapies, and has been recognized for insightful questioning on major earnings calls. Ramadane began her career in equity research after completing her academic training, and her recent work includes contributions to high-profile research pools. She maintains professional credentials consistent with bank analyst roles, though specific FINRA registrations or securities licenses are not publicly listed.

    Dina Ramadane's questions to Xenon Pharmaceuticals (XENE) leadership

    Dina Ramadane's questions to Xenon Pharmaceuticals (XENE) leadership • Q1 2025

    Question

    Dina Ramadane, on for Jason Gerberry, asked where seizure freedom fits within the statistical hierarchy for X-TOLE2 and about assumptions for this endpoint. She also inquired about the lead indication selection for XEN1120 and the desired pharmacology profile from its Phase I trial.

    Answer

    President and CEO Ian Mortimer stated that for XEN1120, the Phase I trial will assess PK and safety, with the goal of advancing into a proof-of-concept study in pain. Chief Medical Officer Dr. Chris Kenney clarified that seizure freedom is not in the statistical hierarchy for the double-blind portion of the study, as it's an endpoint best measured over a longer term, making the open-label extension data the primary focus for that outcome.

    Ask Fintool Equity Research AI

    Dina Ramadane's questions to BLUE leadership

    Dina Ramadane's questions to BLUE leadership • Q2 2024

    Question

    Asked about the drivers for the expected acceleration in LYFGENIA patient starts in the second half of the year and the competitive dynamics influencing prescriber choice between sickle cell gene therapies.

    Answer

    The LYFGENIA acceleration was always anticipated for the second half of the year due to the longer patient journey involving payer approvals and clinical readiness; it is a timing issue, not a demand issue. The company believes it holds a competitive lead due to its larger QTC network, higher U.S. patient start numbers, and favorable market research showing physician preference for LYFGENIA.

    Ask Fintool Equity Research AI